Olanzapine (Zyprexa):characteristics of a new antipsychotic.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.6.11.1743PMID 15989578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

  2009cited by this paper
• What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?

  1997cited by this paper
• Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

  1997cited by this paper
• Efficacy of olanzapine: an overview of pivotal clinical trials.

  1997cited by this paper
• Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.

  1997cited by this paper
• D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects

  1997cited by this paper
• Olanzapine response in therapy-refractory schizophrenia with substance abuse (SA)

  1997cited by this paper
• Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

  1996cited by this paper
• Behavioral effects of sertindole, risperidone, clozapine and haloperidol inCebus monkeys

  1996cited by this paper
• Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine Neurons

  1996cited by this paper
• Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

  1996cited by this paper
• Effects of Olanzapine on Regional C-Fos Expression in Rat Forebrain

  1996cited by this paper
• In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.

  1996cited by this paper
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996cited by this paper
• Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

  1996cited by this paper
• Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

  1995cited by this paper
• First clinical experience with olanzapine (LY 170053): results of an open‐label safety and dose‐ranging study in patients with schizophrenia

  1995cited by this paper
• Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors

  1995cited by this paper
• D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs

  1995cited by this paper
• Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability

  1995cited by this paper
• Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection.

  1995cited by this paper
• Therapeutic receptor-blocking concentrations of neuroleptics

  1995cited by this paper
• Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.

  1994cited by this paper
• Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule

  1994cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

  1976cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

  1976cited by this paper

• Quality by design tool evaluated green stability-indicating UPLC content determination method for the Olanzapine and Samidorphan dosage form

  2024cites this paper
• Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone

  2021cites this paper
• Call for "High-Dose" Olanzapine Research in Treatment-Resistant Psychosis.

  2019cites this paper
• Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum

  2019cites this paper
• Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder

  2019cites this paper
• PD168077, a D4 receptor agonist, reverses object recognition deficits in rats: potential role for D4 receptor mechanisms in improving cognitive dysfunction in schizophrenia

  2011cites this paper
• Functional SNPs in Genes Encoding the 5-HT2A Receptor Modify the Affinity and Potency of Several Atypical Antipsychotic Drugs

  2011cites this paper
• The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.

  2010cites this paper
• Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men.

  2009cites this paper
• Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms

  2009cites this paper
• Chapter 1 Benzoheteropines with Fused Pyrrole, Furan and Thiophene Rings

  2008cites this paper
• Pharmacologic Treatments of Insomnia

  2006cites this paper
• Treatments for chronic psychosis

  2001cites this paper
• N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.

  1999cites this paper
• Developments in antipsychotic drugs - an update.

  1998cites this paper
• Frequency of Psychotic Symptoms in Schizophrenia ( WHO International Pilot Study )

  year unknowncites this paper